What Parenteral Drugs India does

Parenteral Drugs India Limited is a publicly-listed Indian pharmaceutical manufacturer and supplier (BSE: 524689) headquartered in Mumbai, founded in 1983. The company operates in the parenteral (sterile injectable) drug-product segment and is classified as a for-profit, operating entity with a workforce of 1,001–5,000 employees, placing it in the small-to-mid-cap range of Indian specialty sterile manufacturers. The company's commercial surface is its listed-equity status and a corporate website (pdindia.com), although the latter was inaccessible (returning only a verification/loading page) at the time of data aggregation, limiting direct visibility into product portfolio, customer mix, and pricing mechanics.

The underlying business is capital-intensive sterile manufacturing, a regulatory-heavy sub-segment of Indian pharma. However, the most recent disclosed financial trajectory is materially adverse: revenue declined every year from 2018 through 2022, EBITDA turned negative from 2019 onward (negative in four of the five reported years), operating losses widened, and net income was negative in every year on record. The reported revenue figures themselves appear to carry a unit/currency inconsistency in the source, but the directional pattern of decline and persistent unprofitability is unambiguous.

No information on management team, board composition, customer logos, distribution channels, product pipeline, geographic footprint beyond the Mumbai headquarters, M&A history, or capital-raising activity was provided in the input. The investment-relevant question is therefore not what the company does — it manufactures sterile injectables — but whether the persistent losses and top-line contraction reflect cyclical pressure, structural impairment of the asset base, or data-quality artefacts. The absence of disclosed strategic actions, hiring signals, product launches, or partnership activity in the input further limits visibility into any operational turn-around already underway.

Name

Parenteral Drugs India

Website

https://pdindia.com

Company type

Private

Founded year

1983

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Parenteral Drugs India is a publicly-listed Mumbai-based pharmaceutical manufacturer and supplier of parenteral (sterile injectable) drug products, founded in 1983 and operating with 1,001–5,000 employees across the Indian market.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

Keywords

• Pharmaceutical manufacturing
• Parenteral drug production
• Generic medicine supply
• Drug formulation
• Active pharmaceutical ingredients

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales

Core offering

Parenteral Drugs India is a manufacturer and supplier of pharmaceutical products. The company is based in Mumbai, India, and operates in the pharmaceutical manufacturing sector. The source did not provide detail on specific product lines, therapeutic categories, or dosage forms.

Product overview

Unable to extract product and service information from the available source data. The source page displayed a verification/loading message without substantive company content.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Broad incumbents

• Cipla: One of India's largest listed pharmaceutical companies with a broad injectables, APIs and formulations portfolio across domestic and export markets. Comparable as a broad incumbent operating hospital and institutional injectable categories in which Parenteral Drugs India also competes.
• Sun Pharmaceutical Industries: Largest Indian pharma company by revenue, with global sterile manufacturing and a broad hospital injectables franchise. Comparable as a diversified, capital-rich Indian incumbent competing for the same domestic and regulated-market parenteral opportunities.
• Zydus Lifesciences (Cadila Healthcare): Large Indian pharmaceutical group with a diversified injectable portfolio across formulations, biosimilars and APIs. Comparable as another established Indian manufacturer with parenteral and sterile manufacturing operations across multiple segments.
• Aurobindo Pharma: Large Indian generics and APIs manufacturer with a sizeable sterile injectables franchise supplying US, EU and emerging markets. Comparable as another vertically integrated Indian injectable producer operating on a much larger scale than Parenteral Drugs India.
• Dr. Reddy's Laboratories: Major Indian listed pharma with a sizable sterile injectables and hospital business in India and emerging markets. Comparable as a regulated-market Indian injectable competitor with deeper global reach, useful as a benchmark for scale and product breadth.

Direct peers

• Gland Pharma: India-headquartered, listed specialist in sterile injectable generics (vials, ampoules, lyophilised, pre-filled syringes) supplying global regulated markets. Directly comparable to Parenteral Drugs India on product format (parenterals), customer base (hospitals and institutional channels) and India manufacturing footprint.
• Strides Pharma Science: Indian-listed specialty pharma company focused on soft gelatin capsules and sterile injectables with regulated-market approvals. Comparable to Parenteral Drugs India as a focused, injectable-driven Indian manufacturer targeting institutional and export accounts.
• Bharat Serums and Vaccines: India-based, PE-backed injectable and biologic specialty company with strengths in hospital and critical-care products. Comparable as an Indian parenterals specialist competing for the same institutional hospital accounts and select regulated-market tenders.

Emerging players

• Hikal: India-listed API and intermediates manufacturer with growing CDMO capabilities, including for sterile and complex chemistries. Comparable as an Indian specialty manufacturing peer that could supply ingredients into the parenteral value chain or compete for adjacent contract work.

Regional players

• Alkem Laboratories: Indian-listed pharma with a domestic-focused injectables and hospital portfolio across India. Comparable as another listed Indian injectables producer competing in domestic hospital and institutional channels, though with less global export exposure than the largest peers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Parenteral Drugs India